Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF – Free Report) to a strong sell rating in a research report sent to investors on Tuesday, Zacks.com reports.
Separately, Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.
Get Our Latest Research Report on Recordati Industria Chimica e Farmaceutica
Recordati Industria Chimica e Farmaceutica Price Performance
Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%. The company had revenue of $622.00 million for the quarter.
Recordati Industria Chimica e Farmaceutica Company Profile
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
Further Reading
- Five stocks we like better than Recordati Industria Chimica e Farmaceutica
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Texas Roadhouse Stock Steering for New Highs This Year
- ESG Stocks, What Investors Should Know
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Investing in Commodities: What Are They? How to Invest in Them
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Recordati Industria Chimica e Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica e Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.